Welcome to our dedicated page for Odyssey Health news (Ticker: ODYY), a resource for investors and traders seeking the latest updates and insights on Odyssey Health stock.
Odyssey Health, Inc. reports developments tied to its medical technology portfolio, commercial agreements and capital structure. The company focuses on life-saving and life-enhancing medical solutions through acquired or developed assets, intellectual property and technologies. Recent company updates include exclusive worldwide marketing and distribution rights for BreastCheck™ through Odyssey Medical Devices, development work on the patented Save A Life choking rescue device, and commercial service arrangements intended to add recurring revenue.
Odyssey Health news also includes financing facilities, promissory-note activity, operating and financial results, shareholder voting matters, and completed portfolio transactions such as the sale of its neurological drug-therapy assets related to concussion, Niemann Pick Disease Type C, powder formulation technology and a nasal delivery device.
Odyssey Health (OTCQB: ODYY) closed a definitive sub-license granting its subsidiary exclusive worldwide marketing and distribution rights for BreastCheck™, an at-home, non-invasive breast cancer screening device that delivers results in about 15 minutes.
BreastCheck is registered with the U.S. FDA and with EU and UK regulators, and commercial sales are anticipated to begin in the second half of 2026. The company said the product targets recurring usage in an estimated $26 billion global screening market.
Odyssey Health (OTCQB: ODYY) announced a multi-million-dollar, nine-year maintenance service contract for a commercial medical property, which the company says will create a stable, recurring revenue stream and support its transition to cash-generating operations.
The company also secured a financing facility of up to $25 million; an initial tranche of $500,000 will be used to advance Odyssey’s BreastCheck® sub-licensing program for a rapid, non-invasive breast screening test. Management described the deals as improving financial flexibility and enabling strategic commercialization initiatives.
Odyssey Health (OTCQB: ODYY) announced on October 16, 2025 that its subsidiary Odyssey Medical Devices signed a sub-licensing agreement for exclusive worldwide marketing and distribution rights to BreastCheck®, a non-invasive, at-home breast screening test with 15-minute results. The agreement is subject to closing conditions.
BreastCheck® is described as a first-line screening tool (not a mammogram replacement) and the technology is FDA registered in the United States and registered with relevant authorities in the European Union and the United Kingdom. Management expects near-term commercialization and initial revenue, signalling a move from development-stage to revenue-generating medtech.
Odyssey Health (OTCQB: ODYY) has announced plans to advance the development of its patented Save A Life (SAL) choking rescue device, targeting an FDA submission in 2026. The device is designed as a vacuum-based solution for removing lodged objects from a choking victim's throat.
The SAL device features a vacuum chamber with a replaceable mouthpiece that can be quickly deployed in emergencies. When activated, it creates an appropriate vacuum force to dislodge throat obstructions without causing trauma to the victim. The company highlights the significant market need, citing 5,000 annual choking deaths in the US and over 100,000 yearly emergency room visits related to choking incidents.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.